This US patent is the first to be issued in a planned suite of patents related to medication adherence monitoring devices that include an optical dose counter
Adherium, a global leader in digital health technologies that address suboptimal medication use in chronic disease, has been granted a key patent covering medication adherence monitoring devices that include an optical dose counter by the US Patent and Trademark Office, further strengthening the company’s growing intellectual property portfolio.
This US patent is the first to be issued in a planned suite of patents. The optical dose counter allows the device to determine when a dose of medication is being dispensed. Through its SmartInhaler technology, Adherium pioneered the use of add-on adherence monitoring devices with external optical dose counters. This patent confirms Adherium’s ongoing commitment to innovation in the medication adherence market.
'Adherium is committed to improving patient health outcomes through accurate medication monitoring and invests significant effort and resources into Research & Development to achieve this objective,' said Adherium’s Group CEO, Garth Sutherland. 'As a result, Adherium intends to diligently assert its intellectual property rights.'